JP2017500306A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500306A5 JP2017500306A5 JP2016538538A JP2016538538A JP2017500306A5 JP 2017500306 A5 JP2017500306 A5 JP 2017500306A5 JP 2016538538 A JP2016538538 A JP 2016538538A JP 2016538538 A JP2016538538 A JP 2016538538A JP 2017500306 A5 JP2017500306 A5 JP 2017500306A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disorder
- pharmaceutical composition
- patient
- glyx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 238000000034 method Methods 0.000 claims 14
- GIBQQARAXHVEGD-BSOLPCOYSA-N rapastinel Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H]([C@@H](C)O)C(N)=O)CCC1 GIBQQARAXHVEGD-BSOLPCOYSA-N 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 11
- 208000035475 disorder Diseases 0.000 claims 10
- 230000000694 effects Effects 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 8
- 239000000090 biomarker Substances 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 8
- 210000004369 blood Anatomy 0.000 claims 8
- 210000004556 brain Anatomy 0.000 claims 8
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 6
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 6
- 230000001419 dependent effect Effects 0.000 claims 6
- 238000003384 imaging method Methods 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 238000002595 magnetic resonance imaging Methods 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 230000007177 brain activity Effects 0.000 claims 4
- 238000002599 functional magnetic resonance imaging Methods 0.000 claims 4
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 4
- 208000024714 major depressive disease Diseases 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 208000001089 Multiple system atrophy Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 238000005259 measurement Methods 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 208000024412 Friedreich ataxia Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000010496 Heart Arrest Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000030990 Impulse-control disease Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 2
- 208000003435 Optic Neuritis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000009916 Postpartum depression Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000026911 Tuberous sclerosis complex Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 2
- 206010008129 cerebral palsy Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000037326 chronic stress Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 230000008555 neuronal activation Effects 0.000 claims 2
- 229960002715 nicotine Drugs 0.000 claims 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 2
- 238000006213 oxygenation reaction Methods 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000001932 seasonal effect Effects 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000035882 stress Effects 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000009999 tuberous sclerosis Diseases 0.000 claims 2
- 206010008027 Cerebellar atrophy Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 239000008896 Opium Substances 0.000 claims 1
- 206010036790 Productive cough Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 238000001467 acupuncture Methods 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 230000019771 cognition Effects 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 229960001027 opium Drugs 0.000 claims 1
- 210000003802 sputum Anatomy 0.000 claims 1
- 208000024794 sputum Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915835P | 2013-12-13 | 2013-12-13 | |
| US61/915,835 | 2013-12-13 | ||
| PCT/US2014/070340 WO2015089503A2 (en) | 2013-12-13 | 2014-12-15 | Methods of treating brain disorders or identifying biomarkers related thereto |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019153406A Division JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500306A JP2017500306A (ja) | 2017-01-05 |
| JP2017500306A5 true JP2017500306A5 (enExample) | 2018-02-01 |
Family
ID=53371976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016538538A Pending JP2017500306A (ja) | 2013-12-13 | 2014-12-15 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
| JP2019153406A Pending JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019153406A Pending JP2020007333A (ja) | 2013-12-13 | 2019-08-26 | 脳障害を治療する、またはそれに関連した生物マーカーを同定する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160345855A1 (enExample) |
| EP (2) | EP3079579A4 (enExample) |
| JP (2) | JP2017500306A (enExample) |
| CN (2) | CN111920412A (enExample) |
| AU (2) | AU2014361822A1 (enExample) |
| CA (1) | CA2933372A1 (enExample) |
| IL (2) | IL246148A0 (enExample) |
| MX (1) | MX2016007716A (enExample) |
| WO (1) | WO2015089503A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180102052A (ko) * | 2015-10-16 | 2018-09-14 | 노오쓰웨스턴 유니버시티 | 조현병, 양극성 장애, 인지 손상 및 주요 우울 장애의 치료를 위한 비전형적 항정신병약과 nmda 조절제의 약제학적 병용 |
| CN113557028A (zh) * | 2019-01-11 | 2021-10-26 | 诺雷克斯股份有限公司 | 雷帕替奈的盐和晶型 |
| CN110123342B (zh) * | 2019-04-17 | 2021-06-08 | 西北大学 | 一种基于脑电波的网瘾检测方法及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| US20050273017A1 (en) * | 2004-03-26 | 2005-12-08 | Evian Gordon | Collective brain measurement system and method |
| WO2007123799A2 (en) * | 2006-04-03 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Assessing subject's reactivity to psychological stress using fmri |
| CN101505745A (zh) * | 2006-06-15 | 2009-08-12 | 玛尔斯有限公司 | 改善认知功能的方法和组合物 |
| RS53513B1 (sr) * | 2009-10-05 | 2015-02-27 | Northwestern University | Glyx-13 za upotrebu u postupku tretiranja refraktornih depresija |
| US8951968B2 (en) * | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| SG10202010665YA (en) * | 2011-04-27 | 2020-11-27 | Univ Northwestern | Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders |
| WO2013106084A1 (en) * | 2012-01-09 | 2013-07-18 | Takeda Pharmaceutical Company Limited | Methods and drug products for treating alzheimer's disease |
-
2014
- 2014-12-15 MX MX2016007716A patent/MX2016007716A/es unknown
- 2014-12-15 CN CN202010314939.0A patent/CN111920412A/zh active Pending
- 2014-12-15 JP JP2016538538A patent/JP2017500306A/ja active Pending
- 2014-12-15 US US15/104,223 patent/US20160345855A1/en not_active Abandoned
- 2014-12-15 WO PCT/US2014/070340 patent/WO2015089503A2/en not_active Ceased
- 2014-12-15 CA CA2933372A patent/CA2933372A1/en not_active Abandoned
- 2014-12-15 CN CN201480068036.1A patent/CN106102762A/zh active Pending
- 2014-12-15 EP EP14870211.1A patent/EP3079579A4/en not_active Withdrawn
- 2014-12-15 EP EP20174673.2A patent/EP3721799A1/en not_active Withdrawn
- 2014-12-15 AU AU2014361822A patent/AU2014361822A1/en not_active Abandoned
-
2016
- 2016-06-09 IL IL246148A patent/IL246148A0/en unknown
-
2019
- 2019-08-26 JP JP2019153406A patent/JP2020007333A/ja active Pending
- 2019-11-13 AU AU2019264583A patent/AU2019264583A1/en not_active Abandoned
-
2020
- 2020-08-02 IL IL276431A patent/IL276431A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Butovsky et al. | Microglial signatures and their role in health and disease | |
| Merlino et al. | Prevalence of ‘poor sleep’among patients with multiple sclerosis: an independent predictor of mental and physical status | |
| Berry et al. | AASM scoring manual version 2.2 updates: new chapters for scoring infant sleep staging and home sleep apnea testing | |
| Jarus et al. | Effect of internal versus external focus of attention on implicit motor learning in children with developmental coordination disorder | |
| Wang et al. | miR-148b regulates proliferation and differentiation of neural stem cells via Wnt/β-catenin signaling in rat ischemic stroke model | |
| Tripathi et al. | Activation of cell-free mtDNA-TLR9 signaling mediates chronic stress-induced social behavior deficits | |
| Won et al. | Elucidation of relevant neuroinflammation mechanisms using gene expression profiling in patients with amyotrophic lateral sclerosis | |
| JP2017500306A5 (enExample) | ||
| Linden et al. | Neuroimaging in psychiatry: from bench to bedside | |
| Kumar et al. | Neurological disorders and challenges in their Theranostics | |
| Wang et al. | Potential value of cerebrospinal fluid progranulin in the identification of postoperative delirium in geriatrics patients undergoing knee replacement: the perioperative neurocognitive disorder and biomarker LifestylE study | |
| JP2020007333A5 (enExample) | ||
| Hashemi et al. | Neural differentiation of choroid plexus epithelial cells: role of human traumatic cerebrospinal fluid | |
| EA201490548A1 (ru) | Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости | |
| DE602007006284D1 (de) | Verfahren zur vorhersage des ansprechens von patienten mit multipler sklerose auf eine interferontherapie und zur diagnose von multipler sklerose | |
| Balendra et al. | Quo vadis motor neuron disease? | |
| ATE424469T1 (de) | Für prkcb1 kodierendes humanes autismus- suszeptibilitätsgen und dessen verwendung | |
| Fabisch et al. | Sinusoidal smooth pursuit eye tracking at different stimulus frequencies: position error and velocity error before catch-up saccades in schizophrenia and in major depressive disorder | |
| Abdelaal et al. | Differential Expression of Exosomal MicroRNAs in Neurodegenerative Diseases | |
| Le Boterff et al. | A tablet-based quantitative assessment of manual dexterity for detection of early psychosis | |
| Vahia et al. | Successful aging-from research to practice | |
| DE602006017045D1 (de) | Ein transmembranprotein kodierendes humanes autismus-suszeptibilitätsgen und dessen verwendung | |
| Yin et al. | The dopaminergic polymorphisms in psychomotor retardation of depression: a pathway-based imaging genetics association study | |
| Messina et al. | Evolution, morphology and function of the amygdala: Focus on schizophrenia | |
| Liang et al. | WNT genes and their roles in traumatic brain injury |